A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

Trial Profile

A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 23 Aug 2014 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network
    • 31 Mar 2014 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017 according to ClinicalTrials.gov record.
    • 31 Mar 2014 Planned initiation date changed from 1 Feb 2014 to 1 Apr 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top